Cytomegalovirus (CMV) is a DNA virus and a member of the herpes family of viruses, which includes herpes simplex, Epstein-Barr, and varicella zoster viruses. Like these other viruses, once primary infection has occurred CMV establishes itself in the host in a latent form with periodic episodes of reactivation occurring throughout life. Both primary and recurrent infections are associated with viral shedding in urine, saliva, semen, cervical secretions, breast milk, and other body fluids. In healthy people symptoms of CMV infection are often mild and non-specific, or absent altogether, and rarely cause serious illness. However CMV infection can be life threatening to immunocompromised people-such as those with advanced HIV infection, transplant recipients, or very premature infants, and there is a risk of fetal infection and damage when the infection is acquired during pregnancy.
Cytomegalovirus (CMV) is a DNA virus and a member of the herpes family of viruses, which includes herpes simplex, Epstein-Barr, and varicella zoster viruses. Like these other viruses, once primary infection has occurred CMV establishes itself in the host in a latent form with periodic episodes of reactivation occurring throughout life. Both primary and recurrent infections are associated with viral shedding in urine, saliva, semen, cervical secretions, breast milk, and other body fluids. In healthy people symptoms of CMV infection are often mild and non-specific, or absent altogether, and rarely cause serious illness. However CMV infection can be life threatening to immunocompromised people-such as those with advanced HIV infection, transplant recipients, or very premature infants, and there is a risk of fetal infection and damage when the infection is acquired during pregnancy.
CMV seroprevalence in pregnant women
Cytomegalovirus is common in communities all over the world with most people acquiring infection at some time, although the prevalence of past infection in pregnant women varies widely, even between populations within a single country. The age specific seroprevalence found in adults reflects the diVerent patterns of acquisition of CMV in childhood. This is due to several factors associated with the transmission of CMV including breast feeding prevalence and the CMV seroprevalence in breast feeding women, crowding, child rearing arrangements, hygiene standards and practice, the age of onset of sexual activity and the number of sexual partners. Studies carried out in ethnically and socially diverse populations show a high seroprevalence among women of low socioeconomic status compared with those of high socioeconomic status and higher rates of seropositivity among black women and women of Asian and Oriental origin than among white women. In the United Kingdom as a whole, about half of all pregnant women are likely to be seropositive.
Routes of acquisition of infection
Cytomegalovirus is present in body fluids and person to person transmission usually occurs through sexual or close and intimate contact; it is unlikely to be transmitted through casual social interaction. Many studies have shown a relation between markers of sexual activity and acquisition of CMV. 1 Cytomegalovirus can also be transmitted through blood transfusion 2 and organ transplantation. 3 The infant may acquire infection from the mother as a result of intrauterine infection (congenital infection), or after infection acquired through contact with infected genital secretions during passage through the birth canal (intrapartum infection), or postpartum through breast feeding. The virus is commonly present in the genital tract of seropositive women at term, and Reynolds et al 4 reported that 40% of infants born to women shedding virus in late pregnancy acquired CMV infection in early life. Cytomegalovirus can be isolated from breast milk in about 30% of seropositive women, although lower rates of isolation are obtained from colostrum. In a study in the United Kingdom, 33% of infants of seropositive mothers were reported to be infected by 1 year and most of these infections occurred in the first 3 months. 5 The acquisition of CMV among these infants occurred almost exclusively among those that had been breast fed and DNA typing confirmed that the virus was of maternal origin. Infection in later infancy or early childhood may result from prolonged close contact with infected people, particularly other children. Studies have shown that up to 40% of children attending day nurseries will be shedding CMV in their urine and there is evidence of horizontal transmission among children. 6 7 The development of restriction endonuclease analysis and more recently DNA sequencing techniques make it possible to document the spread of infection.
By contrast with intrauterine CMV infection, which is associated with fetal infection and fetal damage, there is little evidence that intrapartum or postpartum infection is associated with adverse outcome, except in the case of the very premature infant. However, large scale long term prospective studies of infection acquired during this period have not been carried out. infection can result in fetal infection. The birth prevalence of congenital CMV infection varies in diVerent parts of the world from about 0.3% to 2.4% of live births, as shown in table 1.
As maternal infections are nearly always asymptomatic and at least 90% of congenitally infected infants have no clinically recognisable signs of infection at birth, most are unrecognised. In western Europe congenital infection occurs in about 3-5/1000 births.
Cytomegalovirus is unusual in that the virus can be transmitted from the mother to her fetus even when she had a primary infection months or years before conception and in the presence of substantial humoral immunity. 19 It is unclear whether these recurrent infections reflect a reactivation of latent virus or are re-infections with a new strain of virus. The proportion of congenital infections attributed to primary and recurrent infection diVers from population to population and reflects to some extent the population prevalence of maternal antibodies.
In western countries the overall risk of acquiring primary infection during pregnancy is estimated to be about 1% for susceptible women, 20 21 but this is likely to vary according to the local seroprevalence. Although the transmission rate after primary infection is about 40%, it is probably closer to 1%-2% after recurrent infection. 22 23 Outcome of congenital infection Although most congenitally infected infants have no associated problems, CMV can result in severe neonatal disease and up to 20% of infected children have associated long term disability. Initial studies, largely based on children admitted to hospital, suggested that the prevalence of defects associated with congenital infection was high. However, subsequent large prospective studies, in which children were systematically screened for congenital CMV, showed much lower rates of adverse sequelae. [24] [25] [26] Although it has been suggested that first trimester infection is associated with a higher risk of damage than infection in the second and third trimester, there is a lack of data to substantiate this, and maternal infection acquired in all trimesters is associated with adverse outcome.
About 10% of congenitally infected infants have symptoms at birth, which may include splenomegaly, hepatomegaly, prolonged neo-natal jaundice, thrombocytopenia, pneumonitis, growth retardation, microcephaly, and occasionally cerebral calcifications. Most infants who are symptomatic at birth have adverse sequelae at follow up. The presence or absence of CNS involvement at birth is indicative of long term outcome and infants with microcephaly and other early neurological abnormalities are likely to have complications. These are often multiple and can include sensorineural hearing loss (SNHL), cerebral palsy, epilepsy, mental retardation, delayed psychomotor development, optic atrophy, expressive language delay, and learning disability; infants with chorioretinitis and extensive central lesions may have visual impairment.
Among a British cohort of 65 newly born infants with confirmed, symptomatic congenital CMV infection who survived to 1 month of age and were followed up prospectively to 3-4 years of age, 29 (45%) had permanent neurological sequelae including gross motor or psychomotor problems or sensorineural deafness. 27 Infants with neurological problems in the neonatal period had a poorer prognosis than those presenting with hepatomegaly, splenomegaly, or purpura: 73% and 30%, respectively, had serious permanent sequelae. Although the neonatal manifestations of congenital CMV infection were similar in type and frequency to those reported in an American series of 34 symptomatic infants, 28 the overall prognosis was better. As the American series was based on referrals to specialist hospitals, there may have been selection of the most severely aVected infants and an overestimate of the risk of subsequent handicap.
By contrast with the high rate of sequelae in symptomatic infants, the prognosis for the remaining 90% of children with no apparent signs of CMV at birth is better. About 5%-10% of congenitally infected asymptomatic infants will have later neurological problems, the most common of which is unilateral or bilateral SNHL. Hearing loss may be progressive, and occasionally of late onset, probably due to continuing viral replication. 29 30 In the United Kingdom congenital CMV has now replaced congenital rubella as the most common viral cause of congenital deafness, and is probably responsible for about 10%-15% of bilateral congenital SNHL, which has an overall prevalence of about 1/1000 births. Other sequelae, including cerebral palsy, microcephaly, and epilepsy have also been reported in children who were apparently asymptomatic at birth, but these outcomes seem to be relatively rare and usually associated with SNHL. In the absence of neurological problems congenital CMV does not seem to have a specific eVect on mental ability. 25 31 32 Thus, 80%-90% of children with congenital CMV will be neurologically and developmentally normal.
Until recently there were only a few case reports of recurrent maternal infection in pregnancy resulting in damage, [33] [34] [35] and it was thought that most aVected children had been exposed to primary maternal infection. However, some more recent studies have been able to classify a greater proportion of maternal infections as primary or recurrent, and these suggest that neurological complications in children born to women who were seropositive before conception are less rare than previously thought. 10 11 36 Nevertheless, the presence of maternal antibody is likely to provide substantial protection, and if transmission occurs the risk of damage is probably lower. 19 23 
Diagnosis of congenital infection
In the absence of a screening programme most congenitally infected infants are not identified as only a few are symptomatic at birth or known to be at risk of infection. The standard diagnostic test is virus culture from urine or saliva collected in the first 3 weeks of life. As infection is commonly acquired during delivery or soon after birth, virus isolation from an infant aged over 3 weeks may reflect acquired infection, even if there are neurological symptoms or hearing loss suggestive of congenital infection.
The presence of immunoglobulin M (IgM) in serum CMV specific in the 3 weeks after birth is also diagnostic of infection but can only be detected in about 70% of congenitally infected newborn infants. 37 Polymerase chain reaction (PCR) of the serum for CMV DNA has proved to be a rapid, sensitive, and specific method for the diagnosis of congenital infection. 38 Viral DNA can also be detected by PCR in, for example, saliva, urine, and cerebrospinal fluid, and is likely to replace routine virus culture for the diagnosis of congenital infection. Polymerase chain reaction of the urine is highly sensitive compared with tissue culture and PCR of the CSF may also be of value for rapid diagnosis in symptomatic newborn infants. 39 The detection of CMV DNA in blood spots routinely collected for the diagnosis of inborn errors of metabolism has been used for the retrospective diagnosis of congenital infection in a few children, with good sensitivity and specificity. 40 This approach oVers the possibility of making a diagnosis of congenital infection in a child presenting with symptoms compatible with CMV after the age of 3 weeks, and the feasibility of this is under study.
Treatment of congenital CMV
Although ganciclovir, foscarnet, and cidofovir are used for the treatment of immunocompromised adults with life or sight threatening CMV disease, only ganciclovir has been evaluated in the treatment of infants with symptomatic disease. Intravenous ganciclovir was used in a phase two dose comparison study to treat severely aVected infants. 41 The higher dose was then taken forward in a randomised controlled phase three study which has been reported in abstract form. 42 Although there was no significant diVerence in mortality or resolution of haematological or hepatic disorders, there was some evidence of protection against hearing deterioration. However most treated infants developed neutropenia. It would seem prudent at the present time to restrict treatment of congenital CMV to infants enrolled in clinical trials, unless clinical judgement warrants exposure to ganciclovir.
Prevention
No treatment is currently available to prevent mother to child transmission of CMV in pregnancy. Prevention of congenital CMV is the major driving force for the development of a vaccine and the American Academy of Sciences has identified CMV vaccine for 12 year olds as a cost eVective strategy for the prevention of congenital CMV. Several candidate vaccines are under development, 43 including a live attenuated strain of CMV (Towne), a recombinant subunit vaccine (gB), and a Canarypox vaccine (ALVAC) incorporating recombinant gB.
Screening and congenital CMV infection
Antenatal screening for CMV infection in pregnancy, and neonatal screening for congenital infection have both been suggested. However, there is currently no safe and eVective treatment to prevent mother to child transmission of CMV or its adverse consequences. The primary purpose of an antenatal screening programme would therefore be to detect asymptomatic primary maternal infection, and establish the infection status of the fetus, so that termination of the pregnancy could be considered. Neonatal screening would facilitate the detection of asymptomatic congenitally infected infants who are at risk of adverse outcome. Both these approaches are reviewed here.
Antenatal screening
In the absence of routine antenatal testing, diagnosis of CMV infection is currently restricted to those few women presenting with symptoms in pregnancy. Several European specialist units providing prenatal diagnosis for women referred with symptomatic CMV infection in pregnancy have reported their results, [44] [45] [46] and all underlined the necessity for multiple investigations in aVected pregnancies, and the diYculties inherent in interpreting the results.
As most maternal CMV infections are asymptomatic, antenatal serological screening would be required to diagnose infections occurring in pregnancy. Women would need to be tested for CMV IgG antibodies at their first antenatal visit and if found to be seronegative and susceptible to infection retested at a later stage to identify those who seroconvert. For women seropositive at the first visit, the presence of CMV specific IgM might indicate infection early in pregnancy, although preconceptual infection could not be excluded as IgM may persist for 3-6 months or even longer after a primary infection, 47 and is sometimes detectable after reinfection.
Newer tests-such as IgG avidity and IgM reactivity by immunoblotting-oVer the prospect of more accurate identification of recent primary infection. 48 However, as estimates of the predictive value of IgG avidity are based on small samples, and these tests are not yet widely available, further studies are needed.
After the confirmation of maternal infection, amniocentesis with PCR to test for CMV DNA in amniotic fluid is required to identify those fetuses that are infected. It is clearly desirable to identify not only whether infection has been transmitted to the fetus, but also the likelihood of damage. A positive result would provide the woman with the opportunity to consider termination of pregnancy although it is not yet possible to diVerentiate reliably between infected fetuses with and without damage. Quantitative PCR on amniotic fluid to identify fetuses with increased viral load, who may be at increased risk, could be one approach. 49 Ultrasound scanning would identify some infants with structural abnormalities, but given the nature of CMV infection, failure to detect problems would not provide conclusive evidence that there were none.
Two screening scenarios are presented here based on diVerent rates of maternal seroprevalence and primary maternal infection, using assumptions that would be most favourable to a potential screening programme (table 2) . For example, estimates of the risk of damage in infected infants are at the upper end of reported figures, and children with unilateral SNHL as the single manifestation of congenital infection are classified as having moderate damage. It is also assumed that the tests for primary infection are perfect, and that all women take up all tests oVered.
Both examples are based on a population of 200 000 pregnant women (table 3) . Women are first tested at 10 weeks of pregnancy with those identified as seronegative tested again at 20 weeks. A diagnosis of primary infection is made by detection of IgM in the first specimen of women screened IgG seropositive, or of seroconversion between 10 and 20 weeks. Women diagnosed with primary infection are oVered amniocentesis, with PCR on amniotic fluid as the diagnostic test for fetal infection. Amniocentesis would be performed at 21 weeks, after diagnosis of a seroconversion at 20 weeks and allowing 1 week for processing results and arranging the investigation. Due to the interval between primary infection and the presence of CMV in amniotic fluid, only fetuses infected in the first 16 weeks of pregnancy are likely to be reliably identified. The sensitivity of the PCR in infected fetuses of women whose infections occur after 16 weeks is not known and is likely to be low.
Scenario one
This scenario reflects the situation in the United Kingdom. It is assumed that 50% of pregnant women are seronegative, the incidence of maternal infection is 1%, and the rate of transmission to the fetus 40% (table 2) . Half the women, 100 000, would be identified as seronegative and 1000 would be diagnosed with primary infection in pregnancy (table 3) . This would result in 400 infected fetuses including 40 who would be severely damaged and 40 moderately damaged at birth, or subsequently. Assuming a constant rate of fetal infection over gestation, only 160 of the 400 infected fetuses would be infected before 16 weeks and detected by PCR on amniotic fluid at 21 weeks. Of these 160 infected fetuses, 16 would have severe damage associated with congenital infection and 16 moderate damage, probably manifesting later in infancy.
Assuming that the PCR test is 100% sensitive and 80% specific (based on work by Lazzarotto et al 48 ) 208 women overall would be diagnosed with infected fetuses, including 48 with false positive results (table 4) . Termination of pregnancy would be oVered to all 208 women. We have not attempted to estimate how many would take up this oVer. As a result of screening, 32 (40%) of the 80 fetuses destined to be damaged after primary maternal infection would be identified. In addition, 48 uninfected fetuses and 128 infected but unaVected fetuses would be identified.
Scenario two
The second scenario reflects the situation in Italy where there is a higher maternal seroprevalence of 85%. 12 The reported incidence of primary infection in diVerent populations of pregnant women ranges from about 0.7% to 4% 20 21 50 according to the demographic profile of the population. The incidence of primary maternal infection is likely to be higher in populations of high seroprevalence, such as in 
Conclusions on antenatal screening
The proportion of aVected infants detected could be higher than estimated above if infection in the first trimester accounts for a disproportionate number of aVected children. However as the uptake of testing at each stage of the programme would be unlikely to reach 100%, the proportion detected would realistically be less than estimated. The scenarios presented are based on the assumption that identification of primary infection in pregnancy is perfect. A complication arises from the likelihood that some women who are IgM positive at antenatal booking would not have had a primary infection in pregnancy. A recent review 39 suggested that only 10% of IgM positive women deliver an infected child; based on a 40% transmission rate this implies a positive predictive value for primary infection of around 25%. Some of these false positive results could be due to recurrent maternal infection. This could increase the number of women undergoing amniocentesis.
Amniocentesis to try to establish whether fetal infection had occurred would be an important component of a screening programme as only about 40% of primary maternal infections lead to fetal infection. Although this procedure could reassure women whose fetuses were not infected, it carries a risk of fetal loss in about 1% of cases, and does not identify whether an infected fetus has been damaged. A relatively small French study of routine antenatal testing was reported by Grangeot-Keros et al 51 in which 4500 women were screened and 20 were diagnosed with suspected or confirmed primary infection. Seventeen amniocenteses were performed, and one was followed by a miscarriage. Nine infected infants were born but only four were diagnosed prenatally, and in a fifth, CMV was not detected in amniotic fluid. The other four infants were not diagnosed antenatally. All nine infants were asymptomatic at last reported follow up, despite minor abnormalities detected by ultrasound or fetal blood sampling in three fetuses.
Pregnancies aVected by maternal reinfection or recurrence of infection would not be identified through antenatal screening for primary infection, unless recurrence was associated with raised IgM at the time of the initial test. Although the risk is thought to be lower than after primary maternal infection, serious damage has been documented in a proportion of these children. The fact that an antenatal screening programme for primary maternal infection would fail to identify this group of children with damage associated with CMV could have an impact on the perceived success of such a programme.
Having reviewed the available information required for the assessment of any potential screening programme, we suggest that it would not be appropriate to introduce routine antenatal screening for CMV in pregnancy at the present time. The likelihood of diagnosing the pregnancies that would have resulted in the birth of a severely damaged infant is low and the fetus would be unaVected in most pregnancies in which termination was oVered. Unlike rubella, where the risk of damage is restricted to early fetal exposure to infection, women who acquire CMV infection late in pregnancy may still deliver an aVected child. However, screening should be kept under review as the development of better diagnostic tests and safe and eVective antiviral drugs would alter the risk benefit balance.
Neonatal screening
The aim of screening newborn infants would be to identify congenitally infected infants who are asymptomatic at birth, but at risk of later problems. Regular follow up could ensure earlier identification of impairments than would otherwise have occurred.
In a population of 200 000 newborn infants with an incidence of congenital infection of 3/1000, as in the United Kingdom, about 600 congenitally infected infants would be born. About 540 of these infants would be asymptomatic at birth and only identifiable by neonatal screening. Fifty to 60 of these infants might develop SNHL. Universal neonatal hearing screening is currently being introduced in the United Kingdom and elsewhere, and should identify those infants with congenital CMV whose hearing loss is detectable at birth. However, delayed onset of SNHL has been documented in congenital CMV infection, and neonatal screening of hearing could fail to 48 29 detect up to 50% of aVected infants. 52 Therefore in a population where neonatal screening of hearing was also routine, as many as 25-30 infants might benefit from the surveillance at a cost of regular examination of over 500 infected children who would be unaVected by their congenital infection. It is questionable whether the magnitude of the potential benefit would outweigh the anxiety caused to the families of the unaVected infants.
